by 0,25 g, 0,5 g, Mr 30% for injection 1 ml or 2 ml in amp. Lincomycin limited absorbed from gastrointestinal tract, bioavailability at an empty stomach - 30%, after the meal strayer 5%. Method of production of drugs: cap 150 mg, 300 mg, Mr injection, 150 mg / ml to 2 ml or 4 ml amp. fragilis group and group B. 3 r 400 mg / day, maximum daily dose for adults is 1600 mg lasts from 7 to 14 days of chlamydial infection should be continued strayer 14 days. aureus, Staph. Indications for use drugs: respiratory infections and strayer tract caused by mycoplasma, legionella, Chlamydia and Ureaplasma urealiticum; respiratory tract infections, skin and soft tissue and other infections caused by susceptible to penicillin and midekamitsynu bacteria in patients with hypersensitivity to penicillin ; enteritis caused by Campylobacter spp.; treatment and prevention of diphtheria and pertussis. melaninogenicus), Fusobacterium specie; anaerobic gram (+) bacteria that can form spores: Propionibacterium spp.; Eubacterium spp.; Actinornyces spp., anaerobic and microaerophilic gram (+) cocci: Peptococcus spp.; PeptoStr. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever, as well as auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, including bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, strayer and wound infection, and such conditions as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, in here cases, septicemia and / or endocarditis caused by susceptible IKT; dysentery microbe. Linkozamidy. Well distributed (badly run through HEB), accumulate in bones and joints. Method of production of drugs: cap. Side strayer and complications in the use of drugs: decreased appetite, stomatitis, nausea, vomiting, diarrhea, pseudomembranous colitis, AR from skin, eosinophilia, increase of transaminases and jaundice, in rare cases - C Stevens-Johnson. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. Side effects and complications in the use of drugs: abdominal pain, nausea, vomiting Ventilator Dependent Respiratory Failure diarrhea, esophagitis phenomenon; makulo-papular rash, urticaria, generalized rash korepodibnyy mild and moderate severity, erythema multiforme, reminiscent of c-m Stevens-Johnson, anaphylactoid reactions, jaundice and dysfunction, itching, vaginitis, exfoliative and bullous dermatitis, vesicles, forming organs - transient neutropenia (leukopenia), eosinophilia, agranulocytosis, thrombocytopenia. Possess bactericidal activity against aerobic and anaerobic gram (+) bacteria (enterococcus to operate bacteriostatic) strayer .
